By Adriano Marchese
Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial.
Shares rose 93% ahead of the morning bell to $105.22.
The Redwood City, Calif., commercial-stage pharmaceutical company said Monday that its treatment relacorilant in conjuction with the chemotherapy drug nab-paclitaxel met the primary endpoint of the Rosella trials, showing improved progression-free survival in patients with platinum-resistant ovarian cancer.
The data showed that patients treated with the combination of relacorilant and chemotherapy experienced a 30% reduction in risk of disease progression compared with patients treated with nab-paclitaxel alone.
Patients with advanced ovarian cancer have had few adequate treatment options, said Alexander Olawaiye, principal investigator in the trial and director of gynecological cancer research at Magee-Women's Hospital of the University of Pittsburgh. He said patients with recurrent forms of the disease eventually develop resistance to available therapies.
"The improvement in survival seen in Rosella, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer," Chief Development Officer Bill Guyer said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 31, 2025 08:55 ET (12:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.